Champions Oncology (CSBR)

• Market cap: $150M
• 1 day: 2.23%
• 5 days: -2.14%
• 1 month: 15.95%
• 3 months: 168.46%
• 6 months: 128.75%
• Year to date: 33.90%
• 1 year: 80.89%
• 5 years: 43.16%
• 10 years: 119.60%
• Sector: Healthcare
• Industry: Biological Products, Except Diagnostic Substances

About: Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.

Employees: 306

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

50% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 4

0% more funds holding in top 10

Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]

0% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 3

0.25% less ownership

Funds ownership: 42.81% [Q2] → 42.56% (-0.25%) [Q3]

4% less funds holding

Funds holding: 23 [Q2] → 22 (-1) [Q3]

6% less capital invested

Capital invested by funds: $30.1M [Q2] → $28.2M (-$1.91M) [Q3]

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $73K

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $8 27% downside
• Avg. target: $8 27% downside
• High target: $8 27% downside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

Craig-Hallum Matt Hewitt 61% 1-year accuracy 14 / 23 met price target

27% downside $8

Buy Maintained

12 Dec 2024